Chemomab Therapeutics (CMMB) Total Current Liabilities (2017 - 2025)
Chemomab Therapeutics' (CMMB) quarterly Total Current Liabilities came in at $1.5 million in Q4 2025, down 54.07% YoY from $3.2 million in Q4 2024, and up 29.99% on a QoQ basis from $1.1 million in Q3 2025.
Chemomab Therapeutics (CMMB) Total Current Liabilities (2017 - 2025) Analysis & Trends
Chemomab Therapeutics (CMMB) has 9 years of Total Current Liabilities data on file, last reported at $1.5 million in Q4 2025.
- Quarterly Total Current Liabilities fell 54.07% year-over-year to $1.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.5 million (down 54.07% YoY) and the FY2025 annual result came in at $1.5 million, down 54.07% from the prior year.
- Total Current Liabilities grew to $1.5 million in Q4 2025, from $1.1 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $7.0 million in Q1 2023 to a low of $1.1 million in Q3 2025.
- A 5-year average of $3.9 million and a median of $4.3 million in 2024 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 236.01% — and 2025, when it sank 73.86%.
- Tracing CMMB's Total Current Liabilities over 5 years: stood at $2.6 million in 2021, then soared by 154.68% to $6.7 million in 2022, then retreated by 28.32% to $4.8 million in 2023, then tumbled by 33.48% to $3.2 million in 2024, then slumped by 54.07% to $1.5 million in 2025.
- The last three Total Current Liabilities figures came in at $1.5 million (Q4 2025), $1.1 million (Q3 2025), and $1.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.92 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.57 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 59.12 Bn | 53.98 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.75 Bn | 28.45 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.72 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.20 Bn | 26.36 Bn | - | 630.93 Mn |
| 10 | Chemomab Therapeutics | 13.07 Mn | 2.71 Mn | - | 1.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.48 Mn |
| Sep 30, 2025 | 1.14 Mn |
| Jun 30, 2025 | 1.43 Mn |
| Mar 31, 2025 | 2.25 Mn |
| Dec 31, 2024 | 3.22 Mn |
| Sep 30, 2024 | 4.35 Mn |
| Jun 30, 2024 | 4.31 Mn |
| Mar 31, 2024 | 4.40 Mn |
| Dec 31, 2023 | 4.84 Mn |
| Sep 30, 2023 | 5.37 Mn |
| Jun 30, 2023 | 6.83 Mn |
| Mar 31, 2023 | 7.00 Mn |
| Dec 31, 2022 | 6.75 Mn |
| Sep 30, 2022 | 5.48 Mn |
| Jun 30, 2022 | 4.39 Mn |
| Mar 31, 2022 | 3.52 Mn |
| Dec 31, 2021 | 2.65 Mn |
| Sep 30, 2021 | 1.63 Mn |
| Jun 30, 2021 | 2.16 Mn |
| Mar 31, 2021 | 4.63 Mn |